Related Experiment Video
Updated: Mar 16, 2026
In Vivo Modeling of the Morbid Human Genome using Danio rerio
Published on: August 24, 2013
The rise of FGF23: should insights from population-based studies inform future clinical trials?
1Division of Nephrology, Hennepin County Medical Center, Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, Minnesota, USA.
Abstract:
Research on the potential effects of fibroblast growth factor 23 (FGD23) in chronic kidney disease (CKD) has been galvanized by work suggesting that the FGF23 level rises even before the parathyroid hormone (PTH) level. However, new work suggests that the levels of both FGF23 and PTH may begin to rise much earlier than previously appreciated, indeed well before the establishment of clinically evident CKD. These findings challenge previous understanding and could affect the design of interventional trials designed to lower FGF23 levels.
More Related Videos
05:44Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development
Published on: May 17, 2024
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
